A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/40 (2006.01) A61K 31/00 (2006.01) A61K 31/135 (2006.01) A61K 31/403 (2006.01) A61K 31/4045 (2006.01) A61K 31/454 (2006.01) A61K 31/48 (2006.01)
Patent
CA 2159767
The present invention provides a method for the treatment of migraine and associated disorders which relies on a novel mechanism of action. By treating a migraineur with compounds or compositions which are selective agonists of 5-HT1F receptors relative to other serotonin receptors which produce unwanted effects like vasoconstriction, the neurogenic meningeal extravasation which leads to the pain of migraine is inhibited and the physiological liabilities of compounds exhibiting vasoconstriction or other side effects are avoided.
Audia James Edmund
Branchek Theresa
Cohen Marlene Lois
Johnson Kirk Willis
Phebus Lee Alan
Eli Lilly And Company
Gowling Lafleur Henderson Llp
LandOfFree
5-ht1f mediated inhibition of neurogenic meningeal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-ht1f mediated inhibition of neurogenic meningeal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-ht1f mediated inhibition of neurogenic meningeal... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1790423